Sanofi (SNYNF) Goodwill & Intangibles (2009 - 2026)
Sanofi's (SNYNF) quarterly Goodwill & Intangibles came in at $80.9 billion in Q1 2026, up 20.5% year-on-year from $67.1 billion in Q1 2025, and down 36.17% quarter-over-quarter from $126.7 billion in Q4 2025.
Sanofi (SNYNF) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Sanofi has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $80.9 billion for Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $80.9 billion, up 20.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.9 billion (up 20.5% YoY), and the FY2025 annual result was $126.7 billion, up 79.64% from the prior year.
- Goodwill & Intangibles came in at $80.9 billion for Q1 2026 at Sanofi, down from $126.7 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $126.7 billion in Q4 2025 to a low of $45.6 billion in Q2 2025.
- The 5-year median for Goodwill & Intangibles is $70.5 billion (2024), against an average of $71.4 billion.
- Peak annual rise in Goodwill & Intangibles reached 79.64% in 2025, while the deepest fall reached 15.45% in 2025.
- Sanofi's Goodwill & Intangibles stood at $73.0 billion in 2022, then climbed by 8.69% to $79.3 billion in 2023, then dropped by 11.07% to $70.5 billion in 2024, then soared by 79.64% to $126.7 billion in 2025, then tumbled by 36.17% to $80.9 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $80.9 billion (Q1 2026), $126.7 billion (Q4 2025), and $80.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 94,972,132.98 Bn | 94,972,128.02 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,006.91 Bn | 1,001.63 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 565.25 Bn | 543.20 Bn | 15.96 Bn |
| 4 | AbbVie | 392.62 Bn | 383.27 Bn | 10.78 Bn |
| 5 | Merck | 285.22 Bn | 279.57 Bn | 12.09 Bn |
| 6 | Amgen | 188.94 Bn | 176.90 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 154.59 Bn | 146.86 Bn | 5.52 Bn |
| 8 | Pfizer | 147.99 Bn | 135.22 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.76 Bn | 104.31 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.88 Bn |
| Dec 31, 2025 | 126.72 Bn |
| Sep 30, 2025 | 80.51 Bn |
| Jun 30, 2025 | 45.60 Bn |
| Mar 31, 2025 | 67.12 Bn |
| Dec 31, 2024 | 70.54 Bn |
| Jun 30, 2024 | 53.93 Bn |
| Dec 31, 2023 | 79.32 Bn |
| Jun 30, 2023 | 53.62 Bn |
| Dec 31, 2022 | 72.98 Bn |
| Jun 30, 2022 | 53.95 Bn |
| Dec 31, 2021 | 79.46 Bn |
| Jun 30, 2021 | 54.17 Bn |
| Dec 31, 2020 | 74.76 Bn |
| Jun 30, 2020 | 49.85 Bn |
| Dec 31, 2019 | 49.28 Bn |
| Jun 30, 2019 | 49.91 Bn |
| Dec 31, 2018 | 75.47 Bn |
| Sep 30, 2018 | 1.15 Bn |
| Jun 30, 2018 | 1.09 Bn |